Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer

Melissa L. Johnson, Egbert F. Smit, Enriqueta Felip, Suresh S. Ramalingam, Myung-Ju Ahn, Anne Tsao, Bruce E. Johnson, Michael Offin, Maen Hussein, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Jeffrey M. Clarke, Marcelo V. Negrao, Rachel E. Sanborn, Daniel Morgensztern, Tiziana Usari, Keith Wilner, Linh Alejandro, Nada Rifi, Xiaosong Zhang, Gregory J. Riely

Open source

DOI: 10.1200/jco-25-02023
Published: 2025-12-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-02023,
  title = {Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer},
  author = {Melissa L. Johnson and Egbert F. Smit and Enriqueta Felip and Suresh S. Ramalingam and Myung-Ju Ahn and Anne Tsao and Bruce E. Johnson and Michael Offin and Maen Hussein and Ibiayi Dagogo-Jack and Jonathan W. Goldman and Jeffrey M. Clarke and Marcelo V. Negrao and Rachel E. Sanborn and Daniel Morgensztern and Tiziana Usari and Keith Wilner and Linh Alejandro and Nada Rifi and Xiaosong Zhang and Gregory J. Riely},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-02023},
  url = {https://doi.org/10.1200/jco-25-02023}
}

RIS

TY  - JOUR
TI  - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer
AU  - Melissa L. Johnson
AU  - Egbert F. Smit
AU  - Enriqueta Felip
AU  - Suresh S. Ramalingam
AU  - Myung-Ju Ahn
AU  - Anne Tsao
AU  - Bruce E. Johnson
AU  - Michael Offin
AU  - Maen Hussein
AU  - Ibiayi Dagogo-Jack
AU  - Jonathan W. Goldman
AU  - Jeffrey M. Clarke
AU  - Marcelo V. Negrao
AU  - Rachel E. Sanborn
AU  - Daniel Morgensztern
AU  - Tiziana Usari
AU  - Keith Wilner
AU  - Linh Alejandro
AU  - Nada Rifi
AU  - Xiaosong Zhang
AU  - Gregory J. Riely
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-02023
UR  - https://doi.org/10.1200/jco-25-02023
ER  -

APA

Johnson, M. L., Smit, E. F., Felip, E., Ramalingam, S. S., Ahn, M., Tsao, A., Johnson, B. E., Offin, M., Hussein, M., Dagogo-Jack, I., Goldman, J. W., Clarke, J. M., Negrao, M. V., Sanborn, R. E., Morgensztern, D., Usari, T., Wilner, K., Alejandro, L., Rifi, N., Zhang, X., & Riely, G. J. (2025). Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02023

Source records

crossref · retrieved 2026-09-27T10:02:19.150Z